Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Show more
Location: 700 Saginaw Drive, Redwood City, CA, 94063, United States | Website: https://www.revmed.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
7.082B
52 Wk Range
$29.17 - $62.40
Previous Close
$38.50
Open
$38.26
Volume
1,402,330
Day Range
$37.85 - $38.47
Enterprise Value
4.884B
Cash
2.103B
Avg Qtr Burn
-147.8M
Insider Ownership
1.99%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RMC-6236 Details RAS mutant Non-small cell lung carcinoma | Phase 3 Data readout | |
Daraxonrasib (RMC-6236) Details Pancreatic ductal adenocarcinoma , Cancer | Phase 3 Data readout | |
Daraxonrasib (RMC-6236) Details Pancreatic ductal adenocarcinoma , Cancer | Phase 3 Initiation | |
Daraxonrasib (RMC-6236) Details Pancreatic ductal adenocarcinoma , Cancer | Phase 3 Initiation | |
RMC-5552 (mTORC1 inhibitor) Details Breast cancer, Renal cell carcinoma, Glioblastoma, Solid tumor/s, Cancer | Phase 1b Data readout | |
RMC-4630 + sotorasib Details Non-small cell lung carcinoma, Cancer | Phase 1b Data readout | |
RMC-6291 (KRASG12C) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
RMC-6291+ pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
RMC-6236+ pembrolizumab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
RMC-9805 (KRASG12D) Details Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
RMC-6236 + RMC-6291 Details Solid tumor/s, Cancer | Phase 1 Update | |
RMC-6236 (RASMULTI) Details Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
RMC-5127 Details no known indication | Phase 1 Initiation | |
RMC-4630 (SHP2 inhibitor) Details Colorectal cancer , Solid tumor/s, Cancer | Failed Discontinued |